References
Kojima T, Hara H, Tsuji A et al (2022) First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590. Esophagus 19(4):683–692. https://doi.org/10.1007/s10388-022-00920-x
Lv H, Tian Y, Li J et al (2022) Neoadjuvant sintilimab plus chemotherapy in resectable locally advanced esophageal squamous cell carcinoma. Front Oncol 12:864533. https://doi.org/10.3389/fonc.2022.864533
Perdigoto AL, Quandt Z, Anderson M et al (2019) Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome. Lancet Diabetes Endocrinol 7(6):421–423. https://doi.org/10.1016/s2213-8587(19)30072-5
Akturk HK, Kahramangil D, Sarwal A et al (2019) Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis. Diabet Med 36(9):1075–1081. https://doi.org/10.1111/dme.14050
Wang K, Li F, Cui Y et al (2019) The association between depression and type 1 diabetes mellitus: Inflammatory cytokines as ferrymen in between? Mediat Inflamm 2019:2987901. https://doi.org/10.1155/2019/2987901
Funding
Funding is provided by the fund for endocrine and metabolic diseases key laboratory of Shanxi Province (Grant Number 202104010910009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors disclosed no relevant. The author(s) declared no potential conflicts of interest with respect to the research, author- ship, and/or publication of this article.
Ethical approval
This study was conducted according to the Shanxi Bethune Hospital Center for Ethics’ advice. For the public release of this case as well as any information or photographs that could be used to identify the person, informed and written permission was sought from them.
Additional information
Managed by Antonio Secchi.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Lai, N., Fan, X. & Liu, S. Sintilimab-induced autoimmune diabetes mellitus manifesting as diabetic ketoacidosis in a patient with advanced esophageal squamous cell carcinoma. Acta Diabetol 61, 675–678 (2024). https://doi.org/10.1007/s00592-023-02232-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-023-02232-7